The court split the claim construction rulings, giving Alnylam wins on two key terms but rejecting its broader narrowing attempts. The case continues toward trial on infringement and validity — monitor for summary judgment motions and trial dates. ONPATTRO revenue is not immediately at risk, but a future adverse ruling could create royalty obligations or an injunction.
Price Chart
Executive Summary
A Markman claim construction ruling in a patent case brought by the University of Texas against Alnylam over its drug ONPATTRO. The court adopted constructions favorable to Alnylam on two key terms — defining 'liposome' narrowly as requiring an inner aqueous medium (excluding micelles) and ruling that the phospholipid component must contain no lysophosphatides — while rejecting Alnylam's proposed constructions on other terms. This is an interlocutory ruling that shifts the probability of eventual infringement liability but does not resolve the case, and the mixed outcome limits its immediate market impact.
Court Ruling Details
Key Facts
- The court construed 'liposome' as 'a lipid vehicle having one or more lipid bilayers or aggregates surrounding an inner aqueous medium,' adopting Alnylam's proposed construction.
- The court ruled that 'the phospholipid is not a lysophosphatidylcholine or lysophosphatidylethanolamine' means 'the phospholipid component contains no lysophosphatidylcholine or lysophosphatidylethanolamine,' also adopting Alnylam's construction.
- The court rejected Alnylam's proposed constructions for 'a lipid component' and 'a phospholipid component,' instead adopting modified versions of the University's proposals.
- The court declined to construe 'a neutral charge' and 'encapsulate the siRNA such that greater than 90% of the liposomes encapsulate siRNA,' finding they have plain and ordinary meaning.
- The case concerns Alnylam's drug ONPATTRO, a commercial product, but no damages or injunction were awarded at this stage.
- This is a Markman (claim construction) ruling — an interlocutory order that does not resolve infringement or validity.
Financial Impact
No damages or financial exposure quantified in the ruling. The case concerns ONPATTRO, a commercial RNAi therapeutic, but this is an early-stage claim construction ruling with no monetary award.
Risk Factors
- Case continues toward trial on infringement and validity — no resolution yet.
- Adverse claim constructions on 'lipid component' and 'phospholipid component' leave room for plaintiff's infringement theory.
- If Alnylam ultimately loses, ONPATTRO could face royalty obligations or an injunction.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion from CourtListener.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-b0d498de6d-ALNY |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 17, 2026 6w ago | Court Ruling | $224.60 $238.27 | ▲ +6.09% | ▲ +8.06% | $226.93 (+1.04%) |
Jul 30, 2026 9w ago | 8-K | $205.48 $236.56 | ▼ −15.13% | ▼ −11.16% | $226.93 (−10.44%) |
Jul 29, 2026 9w ago | Institutional Cluster | $286.62 $239.00 | ▼ −16.61% | ▼ −21.63% | $226.93 (−20.83%) |
Mar 3, 2026 30w ago | Insider Cluster | $318.65 $330.87 | ▲ +3.83% | ▲ +8.24% | $226.93 (−28.79%) |
Mar 3, 2026 30w ago | Insider Cluster | $318.65 $330.87 | ▲ +3.83% | ▲ +8.24% | $226.93 (−28.79%) |
Feb 28, 2026 30w ago | Institutional Cluster | $325.07 $316.09 | ▼ −2.76% | ▲ +5.18% | $226.93 (−30.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more — parsed and scored by AI.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access